[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
K Shi, G Wang, J Pei, J Zhang, J Wang… - Journal of Hematology & …, 2022 - Springer
Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
[HTML][HTML] Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
T Zhang, B Wan, Y Zhao, C Li, H Liu, T Lv… - … lung cancer research, 2019 - ncbi.nlm.nih.gov
Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
W Fang, Y Huang, S Hong, Z Zhang, M Wang, J Gan… - BMC cancer, 2019 - Springer
Background Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations
represent approximately 4–12% of EGFR mutations and are generally refractory to the 1st …
represent approximately 4–12% of EGFR mutations and are generally refractory to the 1st …
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
[HTML][HTML] Targeting EGFR in melanoma–the sea of possibilities to overcome drug resistance
J Pastwińska, K Karaś, I Karwaciak… - Biochimica et Biophysica …, 2022 - Elsevier
Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …
EGFR exon20 insertion mutations in non–small cell lung cancer: Clinical implications and recent advances in targeted therapies
Q Bai, J Wang, X Zhou - Cancer Treatment Reviews, 2023 - Elsevier
The advent of targeted therapies for oncogenic mutations has led to a major paradigm shift
in the management of non–small cell lung cancer (NSCLC). Molecular targets, such as …
in the management of non–small cell lung cancer (NSCLC). Molecular targets, such as …
[HTML][HTML] Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma
T Zhang, B Sun, C Zhong, K Xu, Z Wang… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Background Intrinsic or acquired resistance to epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) is common, thus strategies for the management of EGFR-TKIs …
kinase inhibitors (EGFR-TKIs) is common, thus strategies for the management of EGFR-TKIs …
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and …
A Russo, T Franchina, G Ricciardi, A Battaglia… - International Journal of …, 2019 - mdpi.com
Uncommon Epidermal Growth Factor Receptor (EGFR) mutations represent a distinct and
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …